Actively Recruiting

Early Phase 1
Age: 25Years - 60Years
MALE
NCT04152993

Responsive Neurostimulation for Post-Traumatic Stress Disorder

Led by VA Greater Los Angeles Healthcare System · Updated on 2024-05-28

6

Participants Needed

1

Research Sites

279 weeks

Total Duration

On this page

Sponsors

V

VA Greater Los Angeles Healthcare System

Lead Sponsor

U

University of California, Los Angeles

Collaborating Sponsor

AI-Summary

What this Trial Is About

Post-traumatic stress disorder (PTSD) refractory to treatment is marked by failure of fear extinction and its biological substrate, amygdala reactivity to trauma reminders. Decades of research have clarified the neuronal mechanisms coordinating fear extinction and consolidation. Fear cells and extinction cells in the basolateral amygdala (BLA) alter their firing rate based on the nature of the stimulus and the influence from the medial prefrontal cortex (mPFC) and the ventral hippocampus (vHPC). Together, the BLA, mPFC, and the vHPC form an anxiety-processing network where the BLA links stimulus to emotion, the vHPC provides memory context, and the mPFC coordinates extinction or consolidation. Local field potential (LFP) recordings from the BLA have revealed specific signals that correspond to an enhanced fear state. Previous studies have shown that neuromodulation of the BLA can promote extinction in a rodent model and in a treatment-refractory PTSD patient. This action is likely carried by disrupting fear signals within the BLA; however, continuous neurostimulation may also disrupt normal function of the amygdala. The present application proposes to investigate the use of Responsive Neurostimulation (RNS, Neuropace) in six (6) veterans suffering from severe treatment-resistant PTSD. This dual-activity device will allow us to chronically record LFPs from the BLA under specific conditions such as fear conditioning, exposure to trauma reminders, and emotional memory encoding and retrieval. In addition, the neural activity will be captured during real-life symptoms of flashback and nightmares. These recordings will provide the specific electrophysiological biomarkers of hypervigilance and re-experiencing. The device will then be programmed to detect and treat these biomarkers with a pre-determined electrical pulse. The patients will be followed prospectively using psychological scales but also with functional neuroimaging and electroencephalograms. These modalities will be used to determine the extent of circuit engagement as a result of the therapy. By approaching PTSD from a fear processing mechanism perspective, our project will serve as a proof of concept for other circuit-based therapies in psychiatry. This proposal is a multi-departmental effort involving 11 investigators across 7 departments and requires a close collaboration between clinical and basic scientists. As a result, the findings underlying chronic recordings will bridge the basic science results from fear conditioning research to clinical neural processes in PTSD patients.

CONDITIONS

Official Title

Responsive Neurostimulation for Post-Traumatic Stress Disorder

Who Can Participate

Age: 25Years - 60Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male aged 25-60 years
  • Able to give informed consent and participate in 4-year follow-up including assessments and device adjustments
  • Stable on current psychotropic medication for at least 2 months before implantation and agree not to increase dosage or add new medications for 6 months unless medically necessary
  • Diagnosed with chronic, treatment-refractory PTSD as the primary psychiatric condition causing distress and impairment
  • PTSD diagnosis confirmed by study psychiatrist using clinical interview and CAPS
  • Minimum 5-year illness duration with no 6-month remission during the 2 years prior to study entry
  • Documented failure to respond to at least 3 evidence-based treatments including at least one pharmacologic agent and one trauma-focused cognitive-behavioral therapy
  • If unable to complete trauma-focused psychotherapy, must have begun treatment and stopped due to risks outweighing benefits
  • Completion of all evidence-based psychotherapy at least 3 months before enrollment
  • Baseline CAPS-5 score of 47 or higher with full PTSD criteria met and severity maintained for at least one month
  • Clinically significant occupational or social impairment due to PTSD
  • Presence of a spouse, family member, or friend to confirm symptoms and assist with follow-up
  • Willingness to share unexpected neurological or psychiatric symptoms with study clinicians
  • Other medical conditions stable for at least 1 year (excluding intermittent steroid or chemotherapy use)
Not Eligible

You will not qualify if you...

  • Suicide attempt in the last 2 years or presence of a suicide plan
  • Unstable psychosis or bipolar disorder or significant risk for violence
  • Primary diagnosis other than PTSD per DSM-IV-TR Axis I
  • Started new psychotherapy program within 3 months prior to enrollment
  • Alcohol or illicit substance use disorder within last 6 months or unstable remission
  • Significant neurological conditions including epilepsy, stroke, movement disorders, serious head injury with deficits, or brain MRI abnormalities
  • Uncontrolled medical conditions such as cardiovascular problems or diabetes
  • Uncontrolled chronic pain
  • Baseline Montgomery Asberg Depression Rating Scale score of 28 or higher
  • Use of warfarin
  • Significant abnormality on preoperative brain MRI
  • Electroconvulsive therapy (ECT) in past 6 months
  • Contraindications to MRI or need for recurrent body MRIs
  • Immunosuppression
  • High surgical risk
  • Currently pursuing new or increased disability compensation for PTSD
  • Intracranial implants such as aneurysm clips, shunts, cochlear implants, or electrodes
  • Past cranial neurosurgery
  • Use of investigational drugs within 30 days before baseline
  • Neurovascular or other intracranial conditions
  • Conditions causing significant cognitive impairment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

VA Greater Los Angeles

Los Angeles, California, United States, 90073

Actively Recruiting

Loading map...

Research Team

S

Sonja Hiller

CONTACT

V

Virginia Janovsky

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here